Multidisciplinary Care of a Large Brain Metastasis in a Patient with Hormone-Receptor-Positive Breast Cancer with Ataxia-Telangiectasia Mutation

Author:

Chelariu-Raicu Anca12ORCID,Piha-Paul Sarina A.3,Chavez-MacGregor Mariana45,Johnson Jason6,Sawaya Raymond7,McAleer Mary Frances8,Nguyen Alissa6,Hartnett Audrey3,Tsimberidou Apostolia M.3,Meric-Bernstam Funda3910,Dumbrava Ecaterina E.3

Affiliation:

1. 1 Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

2. 2 Department of Obstetrics and Gynecology, Breast Center, Gynecologic Oncology Center, and CCC Munich, LMU University Hospital, Munich, Germany

3. 3 Department of Investigational Cancer Therapeutics, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA

4. 4 Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

5. 5 Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

6. 6 Department of Neuroradiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

7. 7 Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

8. 8 Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

9. 9 Department of Breast Surgical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA

10. 10 The Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Abstract

ABSTRACT Poly (adenosine diphosphate-ribose) polymerase inhibitors (PARP)i are emerging as standard oncology treatments in various tumor types. The indications will expand as PARPi are being investigated in various breast cancer subtypes. Currently, except for BRCA1/2 mutation carriers with human epidermal growth factor receptor 2 (HER2)-negative breast cancer, there is inadequate identification of predictive biomarkers of response. We present a 57-year-old woman with metastatic breast cancer, hormone-receptor-positive, HER2 negative with a germline ataxia-telangiectasia mutation with a large brain metastasis with clinical benefit to talazoparib. This case report exemplifies the importance of the multidisciplinary management of patients with brain metastases and personalized biomarker selected treatment.

Publisher

Innovative Healthcare Institute

Subject

Cancer Research,Oncology,Immunology,Immunology and Allergy

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3